Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02488564
Other study ID # IRST174.09
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 17, 2014
Est. completion date April 2020

Study information

Verified date April 2020
Source Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is a multicenter, open-label, two stage phase II trial, to assess activity, safety and potential early predictors of response in neoadjuvant setting. Patients with operable breast cancer (T1c and cytologically N1-2, or cT2-3, N0-N2, M0) or locally advanced breast cancer (T4a-d, N0-N2, M0) with overexpression or amplification of HER2 (AJCC 7th edition 2010) are included in the study.

The primary objective is to evaluate the pathological complete response rate (pCR).

The secondary objectives are:

- to evaluate the clinical response rate (RR).

- to evaluate the feasibility and systemic tolerance, with particular attention to cardiac toxicity.

- to evaluate the conservative surgery rate.

Total duration of the trial is 36 months; planned treatment are 6 cycles of chemotherapy. At every cycle (every 21 days) will be administered:

Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections. Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.


Description:

Multi-center, open-label phase II trial to assess activity of this chemotherapy scheme evaluated by pathologic complete response rate (pCR).

Planned treatment are 6 cycles of chemotherapy.

At every cycle (every 21 days) will be administered:

Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.

Total duration of the trial: 36 months Enrollment period: 24 months Treatment: maximum of 6 cycles (5 months) per patient Follow-up for recurrence: every six months for 5 years, than once a year until 10 years after surgery.It's necessary to recruit 46 patients for clinical objectives evaluation.


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date April 2020
Est. primary completion date October 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients must have histologically confirmed breast cancer

- HER2 overexpressing cancer

- Patients with operable breast cancer (T1c and cytologically N1-2, or cT2-3, N0-N2, M0) or locally advanced breast cancer (T4a-d, N0-N2, M0) (AJCC 7th edition 2010).

- No prior therapy for breast cancer

- Both sexes, age = 18 years and < 75 years

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Life expectancy > 3 months

- Neutrophil count = 2 x 109/ L, leukocytes count = 3 x 109/ L and platelet count = 100 x 109/ L

- Total bilirubin = 1 upper-normal limits (UNL) of the Institutional normal values and alanine aminotransferase (ASAT (GOT) and/or alanine aminotransferase ALAT (GPT) = 2.5 UNL, alkaline phosphatase = 5 UNL. Patients with ASAT and/or ALAT > 1.5 UNL and alkaline phosphatase > 2.5 UNL aren't eligible for the trial.

- Creatinine = 1.5 mg/dL

- Left ventricular ejection fraction (LVEF) = 50% (evaluated by echocardiogram or multiple gated acquisition scan (MUGA) scan -only one method must be employed for each patient)

- Written informed consent

- Homa Index calculated using the Matthews'formula

EXCLUSION CRITERIA:

- Prior chemotherapy or radiotherapy for breast cancer.

- History of prior malignancy in the last 10 years (other than non-melanoma skin cancer or excised cervical carcinoma in situ).

- Other serious illness or medical condition

- Congestive heart failure or angina pectoris even if medically controlled. Previous history of myocardial infarction, uncontrolled high risk hypertension or arrhythmia

- History of significant neurologic or psychiatric disorders including dementia or seizures

- Active infection

- Concurrent treatment with other experimental drugs.

- Participation in another clinical trial with any investigational agents within 30 days prior to study screening.

- Geographic inaccessibility to treatment and followup

- Pregnant and lactating women

- Diabetes-insulin dependant and non-insulin dependant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Liposomal doxorubicin
50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
Docetaxel
30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
Trastuzumab
4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
Metformin
It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.

Locations

Country Name City State
Italy Oncologia Medica AOU Ferrara Ferrara FE
Italy Day Hospital Oncologico, Ospedale Guastalla Guastalla
Italy Oncologia Medica AUSL Imola Imola
Italy IRST Oncologia medica Meldola FC
Italy Oncologia Medica, Policlinico di Modena Modena MO
Italy Oncologia Medica AOU Parma Parma
Italy Oncologia Medica Ospedale Guglielmo da Saliceto Piacenza PC
Italy Oncologia , IRCCS azienda ospedaliera S.Maria Nuova Reggio Emilia RE
Italy U.O Oncologia AUSLdella Romagna Rimini RN

Sponsors (1)

Lead Sponsor Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathologic complete response rate(pCR) Complete pathologic response will be defined as no invasive residuals in breast and axillary nodes. In situ tumor residuals are considered as complete response rate up to 36 months
Secondary clinical response rate (RR) The clinical response rate (RR) will be including Pathological Complete Response, Clinical Complete Response and Clinical Partial Response (Response Evaluation Criteria in Solid Tumors (RECIST) criteria). up to 36 months
Secondary evaluation of toxicity All patients will be evaluable for toxicity from the time of their first treatment with Metformine. The toxicity will be recorded according to the CTC-AE, version 4.0 in the safety population until Follow-up is completed (36 months) up to 36 months
Secondary conservative surgery rate evaluation of the number of patients who underwent conservative surgery up to 36 months
See also
  Status Clinical Trial Phase
Completed NCT01305941 - A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Phase 2
Completed NCT01432223 - Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab Phase 2
Completed NCT01433926 - Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years N/A
Recruiting NCT05871918 - A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer Phase 3
Terminated NCT02598310 - Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer Phase 2
Active, not recruiting NCT02568839 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer Phase 2/Phase 3
Completed NCT02675231 - A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer Phase 2
Terminated NCT02154529 - Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT01565200 - HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 Phase 2
Completed NCT01340430 - Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer Phase 2
Active, not recruiting NCT02947685 - Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Phase 3
Completed NCT02066532 - Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Phase 1/Phase 2
Completed NCT01583426 - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Phase 3
Completed NCT01677455 - An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer Phase 2
Withdrawn NCT01361945 - AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT02326974 - T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA Phase 2
Not yet recruiting NCT04644406 - PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
Terminated NCT02131506 - A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer Phase 1
Completed NCT00788931 - A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer Phase 1
Completed NCT02492711 - Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Phase 3